Document is current
Any future updates will be listed below
-
Authors
Matsukawa, Akihiro https://orcid.org/0000-0002-3324-762X
Yanagisawa, Takafumi https://orcid.org/0000-0002-7410-0712
Fazekas, Tamas
Miszczyk, Marcin https://orcid.org/0000-0002-4375-0827
Tsuboi, Ichiro https://orcid.org/0000-0002-3135-8262
Kardoust Parizi, Mehdi
Laukhtina, Ekaterina https://orcid.org/0000-0002-8953-0272
Klemm, Jakob
Mancon, Stefano
Mori, Keiichiro
Kimura, Shoji
Miki, Jun
Gomez Rivas, Juan https://orcid.org/0000-0002-0556-3035
Soeterik, Timo F. W. https://orcid.org/0000-0002-0259-8750
Zilli, Thomas
Tilki, Derya https://orcid.org/0000-0001-7033-1380
Joniau, Steven https://orcid.org/0000-0003-3195-9890
Kimura, Takahiro https://orcid.org/0000-0002-5673-1553
Shariat, Shahrokh F. https://orcid.org/0000-0002-6627-6179
Rajwa, Pawel https://orcid.org/0000-0003-4073-6584
- License Information
-
More Information
Article History
Received: 30 March 2024
Revised: 19 August 2024
Accepted: 28 August 2024
First Online: 13 September 2024
Competing interests
: Takahiro Kimura is a paid consultant/advisor of Astellas, Bayer, Janssen and Sanofi. Shahrokh F. Shariat received follows: Honoraria: Astellas, Astra Zeneca, BMS, Ferring, Ipsen, Janssen, MSD, Olympus, Pfizer, Roche, Takeda. Consulting or Advisory Role: Astellas, Astra Zeneca, BMS, Ferring, Ipsen, Janssen, MSD, Olympus, Pfizer, Pierre Fabre, Roche, Takeda. Speakers Bureau: Astellas, Astra Zeneca, Bayer, BMS, Ferring, Ipsen, Janssen, MSD, Olympus, Pfizer, Richard Wolf, Roche, Takeda. The other authors declare no conflicts of interest associated with this manuscript. Pawel Rajwa is a paid consultant/advisor of Janssen.
